Censavudine - Oncolys Biopharma

Drug Profile

Censavudine - Oncolys Biopharma

Alternative Names: 4'-Ethynyl-d4T - Oncolys BioPharma; 4'-ethynylstavudine; BMS-986001; Ed4T; Festinavir; OBP-601

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kagoshima University; Yale University
  • Developer Bristol-Myers Squibb
  • Class Antivirals; Furans; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - HIV-1 infections

Highest Development Phases

  • Phase II HIV-1 infections

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 14 Aug 2017 Censavudine is still at phase II development stage for HIV-1 infections in countries worldwide (PO) (Oncolys BioPharma pipeline, August 2017)
  • 29 Jun 2017 Oncolys BioPharma completes a phase II trial in HIV infection in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top